deltatrials
Completed PHASE2 INTERVENTIONAL 2-arm NCT00163761

Efficacy Study of Outpatient Therapy for Lymphoma

A Multicentre Phase II Study of Risk-adjusted Outpatient-based Salvage Therapy for Patients With Relapsed and Refractory Lymphoma

Sponsor: Bayside Health

Conditions Hodgkin's Disease Non-Hodgkin's Lymphoma
Interventions gemcitabine, vinorelbine, filgastrim gemcitabine, vinorelbine, ifosfamide, filgastrim
Updated 5 times since 2017 Last updated: Jan 6, 2016 Started: Dec 31, 2002 Primary completion: Feb 29, 2008 Completion: Feb 29, 2008
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Hodgkin's Disease and Non-Hodgkin's Lymphoma and is currently completed. Bayside Health leads this study, which shows 5 recorded versions since 2002 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jan 2017 – ~Jun 2018 · 17 months · monthly snapshotCompleted~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotCompleted~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 21 months · monthly snapshotCompleted

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

  5. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE2

    First recorded

Dec 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Bayside Health
Data source: Bayside Health

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations